HDAC inhibitors (HDACis) are promising therapies for several types of cancer, such as breast cancer [15], colon cancer [16], hepatocellular carcinoma [17], and medulloblastoma [18], because they increase the susceptibility of tumor cells to apoptosis. This evidence concerns the gene HDAC9 and breast cancer.